Clinical Trial Update: Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 [Phase 2]

View source ↗

Summary

Phase 2 trial comparing erlotinib to standard chemotherapy in patients with advanced non-small cell lung cancer and ECOG performance status 2 has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Standard chemotherapy

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-04-22